-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on BeOne Medicines, Raises Price Target to $435

Benzinga·11/06/2026 14:52:15
Listen to the news
Wells Fargo analyst Yanan Zhu maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $400 to $435.